CTC Alternative Strategies’s Avanos Medical AVNS Stock Holding History

CTC Alternative Strategies’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-7,700	Closed	-$379K	–	41
2015 Q1	$379K	Hold	7,700	–	–	1.01%	16
2014 Q4	$350K	Buy	+7,700	New	+$303K	0.7%	33

Other funds holding AVNS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

RR Partners New York $929M AUM 110.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

CTC Alternative Strategies's AVNS Position: Q2 2015 in Review

CTC Alternative Strategies sold out of Avanos Medical (AVNS) in Q2 2015, closing a stake of 7,700 shares — an estimated $379K sold.

CTC Alternative Strategies first reported a position in AVNS in Q4 2014 and held it in 2 quarters. The position peaked at $379K in Q1 2015. 419 funds tracked by Wall St. Rank hold AVNS as of Q2 2015.

CTC Alternative Strategies reported no remaining Avanos Medical position as of Q2 2015 after selling out during the quarter.
CTC Alternative Strategies sold 7,700 Avanos Medical shares in Q2 2015, an estimated $379K.
CTC Alternative Strategies first reported a position in Avanos Medical in Q4 2014 and held it in 2 quarters.
CTC Alternative Strategies's Avanos Medical position peaked at $379K in Q1 2015.
419 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2015.

Based on CTC Alternative Strategies's 13F filing for Q2 2015, filed 13 Aug 2015.